J&J Wins FDA Approval for Diabetes Combo Drug
J&J’s Janssen Pharmaceuticals unit was granted FDA approval for Invokamet, a fixed-dose therapy combining canagliflozin and metformin hydrochloride in a single tablet, for the treatment of adults with type 2 diabetes.
According to J&J, Invokamet combines the SGLT2 blocker canagliflozin (approved in March 2013) with the commonly prescribed treatment metformin, creating a single tablet that lowered blood sugar, lowered blood pressure and reduced body weight in Phase III trials.
Invokamet is the first fixed-dose combination of an SGLT2 inhibitor with metformin approved in the United States.
Read the press release